A cloud-based SaaS platform linking MedX's native SIAscope imaging devices to CRO and sponsor workflows.
Mapping collagen, melanin and haemoglobin in skin in around 30 seconds, without any need for biopsy.
MISSISSAUGA, Ontario, June 26, 2026--(BUSINESS WIRE)--MedX Health Corp. (TSXV: MDX) today announced the commercial launch of SkinSecure™, a cloud-based SaaS platform that links the Company's native SIAscope multi-spectral imaging devices directly to Contract Research Organization (CRO) workflows. SkinSecure™ maps collagen, melanin and hemoglobin in living skin in a single capture, giving skin trials immediate, objective biomarker data across multiple sites and multiple subjects, with instant shared access to every result. Built on MedX's patented SIAscopy™ technology, which powers its FDA-approved DermSecure™ platform and backed by more than 30 years of peer-reviewed scientific heritage, SkinSecure™ fits directly into established trial protocols. For collagen endpoints, it offers an alternative to expensive, invasive punch biopsies.
"Medicine established objective ways to measure our major systems long ago - the ECG for the heart, the EEG for the brain, the blood panel for what flows between them," said John Gevisser, Chief Executive Officer of MedX Health. "Each became a standard. But what about skin, the body's largest organ? We come at this challenge from first principles, and this gives us the method and the science to establish a new standard. It also enables us to track genuine biological change precisely over time and, uniquely, to measure collagen in absolute rather than relative or derivative terms."
Enhancing How the Industry Measures Skin Biology
The global collagen market is valued at USD 5.2 billion in 2025 and forecast to reach USD 8.7 billion by 2034*, at a compound annual growth rate of 5.8% (Global Market Insights, 2025). This is the entry segment for SkinSecure™, spanning dermatology trials, aesthetic biostimulator studies, topical skincare validation, and MedSpa efficacy research. The non-invasive quantitative collagen measurement capacity of SkinSecure™ also unlocks materially-larger adjacent sectors:
pharmaceutical therapeutic development (anti-fibrotic, regenerative medicine, oncology, wound healing),
injectable and biologic biostimulators,
ingestible and nutraceutical validation,
energy-based medical devices and longevity research.
Across all of them, sponsors today rely on invasive biopsy or indirect surrogate endpoints, because no direct, quantitative in vivo collagen standard currently exists. Many CRO's already run collagen-dependent programmes without a scalable biomarker - making SkinSecure™ a direct workflow replacement, not a speculative use case. MedX is not entering a device category; it is establishing the quantitative standard by which skin biology will be measured in vivo across clinical research, aesthetics and consumer health.